Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.57 |
| ▸ | FASN | P49327 | 4/20 | 0.53 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.48 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.48 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.48 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.48 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.48 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.48 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4455323 | 0.80 | MAPT (1.00) | MAPTKDM4EFASNGRIN2DGRIN3B | |
| SCHEMBL1077245 | 0.75 | MAPT (0.58) | MAPTKDM4E | |
| SCHEMBL8783774 | 0.74 | FASN (0.74) | MAPTKDM4EFASNGRIN2DGRIN3B | |
| SCHEMBL4460818 | 0.74 | MAPT (0.65) | MAPTKDM4EFASN | |
| SCHEMBL1039795 | 0.73 | MAPT (0.59) | MAPTKDM4EFASNGRIN2DGRIN3B | |
| SCHEMBL14449851 | 0.73 | KDM4E (0.70) | MAPTKDM4EFASNGRIN2DGRIN3B | |
| SCHEMBL15648185 | 0.73 | KDM4E (0.70) | MAPTKDM4EFASN | |
| SCHEMBL5330425 | 0.73 | KDM4E (0.70) | MAPTKDM4EFASN | |
| SCHEMBL8783594 | 0.73 | MAPT (0.68) | MAPTKDM4EFASN | |
| SCHEMBL1612505 | 0.73 | KDM4E (0.79) | MAPTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1915150-B1 | USE OF THIENOPYRIDONE DERIVATIVES AS AMPK ACTIVATORS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | MERCK PATENT GMBH (DE) | 2011-01-26 | — | — | EP | disclosed |
| US-20090105293-A1 | USE OF THIENOPYRIDONE DERIVATIVES AS AMPK ACTIVATORS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | MERCK PATENT GESELLSCHAFT (DE) | 2009-04-23 | — | — | US | disclosed |
| EP-1915150-A1 | USE OF THIENOPYRIDONE DERIVATIVES AS AMPK ACTIVATORS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Merck Patent GmbH (DE) | 2008-04-30 | — | — | EP | disclosed |
| WO-2007019914-A1 | USE OF THIENOPYRIDONE DERIVATIVES AS AMPK ACTIVATORS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | MERCK PATENT GMBH (DE) | 2007-02-22 | — | — | WO | disclosed |
| EP-1754483-A1 | Use of thienopyridone derivatives as AMPK activators and pharmaceutical compositions containing them | Merck Sante (FR) | 2007-02-21 | — | — | EP | disclosed |
| US-5602144-A | ADMINISTERING FOR TREATMENT OF CEREBRAL ISCHAEMIA OR SCHIZOPHRENIA | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1997-02-11 | — | — | US | disclosed |
| EP-0717044-A1 | Thienopyridone derivatives, their preparation and their use as NMDA-receptor antagonists | MERCK PATENT GmbH (DE) | 1996-06-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105293-A1 | USE OF THIENOPYRIDONE DERIVATIVES AS AMPK ACTIVATORS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | PRKAR2A, PRKAR2B, PRKAB1 | MAPT 2498/4885KDM4E 2104/4885FASN 1086/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.